Cargando…

Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

PURPOSE: To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab (IVR) versus bevacizumab (IVB), at a corrected age of 3 years. METHODS: A retrospective case series compared cycloplegic refractive status...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yen-Chih, Chen, San-Ni, Yang, Benjamin Chi-Lan, Lee, Kun-Hsien, Chuang, Chih-Chun, Cheng, Chieh-Yin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866885/ https://www.ncbi.nlm.nih.gov/pubmed/29713524 http://dx.doi.org/10.1155/2018/4565216

Ejemplares similares

Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity
por: Pawar, Neelam, et al.
Publicado: (2023)

Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity
por: Li, Xiu-Juan, et al.
Publicado: (2016)

Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity
por: Hoppe, Charis, et al.
Publicado: (2022)

Pulmonary function in school-age children following intravitreal injection of bevacizumab for retinopathy of prematurity
por: Huang, Ching-Yen, et al.
Publicado: (2022)

Intravitreal Injection of Bevacizumab for Retinopathy of Prematurity in an Infant with Peters Anomaly
por: Minami, Tsuyoshi, et al.
Publicado: (2014)

Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity
por: Simmons, Michael, et al.
Publicado: (2021)

Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
por: Lin, Chun-Ju, et al.
Publicado: (2016)

Intravitreal ranibizumab as salvage therapy in an extremely low–birth-weight infant with rush type retinopathy of prematurity
por: Lin, Chun-Ju, et al.
Publicado: (2012)

Ocular and Systemic Results of Intravitreal Bevacizumab Injection in Retinopathy of Prematurity Treatment
por: Cevik, Sadik Gorkem, et al.
Publicado: (2020)

Comparison of intravitreal injection of ranibizumab versus bevacizumab for treatment of type 1 and aggressive retinopathy of prematurity in rural Egypt. A randomized clinical trial
por: Tawfik, Ghada Mahmoud, et al.
Publicado: (2022)

Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity
por: Chen, Xuting, et al.
Publicado: (2019)

Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage
por: Xu, Yu, et al.
Publicado: (2016)

Inhalation Anesthesia with Sevoflurane during Intravitreal Bevacizumab Injection in Infants with Retinopathy of Prematurity
por: Tokgöz, Orhan, et al.
Publicado: (2013)

Treatment of Radiation Retinopathy with Intravitreal Injection of Ranibizumab (Lucentis(®))
por: Horowitz, Soraya Alessandra, et al.
Publicado: (2020)

COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY
por: Zhang, Guoming, et al.
Publicado: (2017)

Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment
por: Chang, Yu-Shan, et al.
Publicado: (2019)

Combination of Intravitreal Ranibizumab and Laser Photocoagulation for Aggressive Posterior Retinopathy of Prematurity
por: Mota, Ágata, et al.
Publicado: (2012)

Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy
por: Chan, Joyce J. T., et al.
Publicado: (2016)

Intravitreal ranibizumab for retinopathy of prematurity: The ocular and systemic safety profile query
por: Al Kalbani, Khulood, et al.
Publicado: (2023)

Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain
por: Obata, Shumpei, et al.
Publicado: (2021)

Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity
por: Zhao, Jinfeng, et al.
Publicado: (2020)

Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors
por: Bazvand, Fatemeh, et al.
Publicado: (2021)

Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity
por: Arámbulo, Odalis, et al.
Publicado: (2015)

Combination therapy of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity
por: Dudani, Ajay I, et al.
Publicado: (2022)

Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration
por: Sahin, Ozlem, et al.
Publicado: (2023)

Posterior Pole Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab Injection in Posterior Retinopathy of Prematurity
por: Kim, Rebecca, et al.
Publicado: (2014)

Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity
por: Roohipoor, Ramak, et al.
Publicado: (2018)

Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity
por: Obata, Shumpei, et al.
Publicado: (2019)

Role of deferred retinal laser following intravitreal injection of bevacizumab in treatment of severe retinopathy of prematurity
por: Bhat, Vishalakshi, et al.
Publicado: (2023)

Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases
por: Chen, Yen-Po, et al.
Publicado: (2019)

Refractive and ocular biometric profile of children with a history of laser treatment for retinopathy of prematurity
por: Kaur, Savleen, et al.
Publicado: (2017)

Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
por: Huang, Qiujing, et al.
Publicado: (2017)

Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity
por: Chandra, Parijat, et al.
Publicado: (2019)

Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity
por: Arima, Mitsuru, et al.
Publicado: (2020)

Early Experience with Intravitreal Bevacizumab Combined with Laser Treatment for Retinopathy of Prematurity
por: Raizada, Seemant, et al.
Publicado: (2011)

Early Experience with Intravitreal Bevacizumab Combined with Laser Treatment for Retinopathy of Prematurity
por: Ahmed, Ayesha E., et al.
Publicado: (2010)

Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis
por: Sniegowski, Matthew, et al.
Publicado: (2010)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Intraocular Pressure Changes after Intravitreal Bevacizumab or Ranibizumab Injection: A Retrospective Study
por: Mansoori, Tarannum, et al.
Publicado: (2021)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_64n0a8fq3b9pvn56uu78e9d7am